Avenacy debuts generic Lasix
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, is introducing Furosemide for Injection, which is the generic of Lasix.
Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired, Avenacy said.
[Read more: AAM report: Generics, biosimilars generated $373B savings in 2021]
“The launch of Furosemide for Injection builds on the two launches announced earlier this week and further demonstrates the speed at which we are progressing the business,” said Jeff Yordon, co-founder and CEO of Avenacy. “The reception by potential partners and investors to Avenacy at DCAT has been outstanding and, with five products now launched since our formation in October, we look forward to continuing to execute against our goal of launching more than 20 products this year.”
Avenacy's Furosemide will come in packs of 25 units of 100 mg/10 ml doses.
In line with Avenacy’s mission to champion patient safety and streamline patient care, Furosemide for Injection will feature the company’s highly differentiated packaging and labeling to support accurate medication selection, the company noted.
Avenacy will begin shipping Furosemide for Injection to wholesale partners next week. The company is supported by a global network of development and FDA-approved cGMP-certified contract manufacturing partners.
[Read more: Avenacy launches 2 new generics]
Furosemide for Injection had a market value of approximately $33 million for the 12 months ending in June 2023, per IQVIA.